Byfavo

Active Ingredient(s): Remimazolam
FDA Approved: * July 2, 2020
Pharm Company: * COSMO TECHNOLOGIES LTD
Category: Anesthetic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Byfavo Overview

Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults lasting 30 minutes or less.[2][3][4] is a benzodiazepine derivative drug, developed by PAION, in collaboration with Japanese licensee Ono Pharmaceutical as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Remim...

Read more Byfavo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Remimazolam

Recent Byfavo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Remimazolam
  • Injection: 20mg
  • Powder: 20mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Remimazolam or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 4 December 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA